Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 4/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 6/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2567464 | 0.93 | MCL1 (0.43) | PTGER4JAK2MCL1HCRTR1HCRTR2 | |
| SCHEMBL12284170 | 0.90 | PTGER4 (0.36) | PTGER4JAK2MCL1ALOX5APHCRTR1 | |
| SCHEMBL12284363 | 0.90 | PTGER4 (0.36) | PTGER4JAK2MCL1ALOX5APHCRTR1 | |
| SCHEMBL12284849 | 0.88 | PTGER4 (0.49) | PTGER4HCRTR1HCRTR2 | |
| SCHEMBL2576435 | 0.86 | PTGER4 (0.41) | PTGER4HCRTR1HCRTR2 | |
| SCHEMBL14575880 | 0.85 | KDM4E (0.39) | PTGER4BRD4KDM4E | |
| SCHEMBL14576203 | 0.82 | PTGER4 (0.51) | PTGER4MCL1 | |
| SCHEMBL12284289 | 0.81 | PTGER4 (0.35) | PTGER4HCRTR1HCRTR2BRD4KDM4E | |
| SCHEMBL2552453 | 0.81 | USP2 (0.40) | PTGER4KDM4EALDH1A1GAAHPGD | |
| SCHEMBL12283704 | 0.81 | PTGER4 (0.49) | PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | claimed |
| EP-2552208-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-02-06 | — | — | EP | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| WO-2011123609-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123609-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K3 | PTGER4 3190/4885JAK2 95/4885MCL1 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.